Lead Product(s) : Pamiparib,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Ivy Brain Tumor Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients, reaches pharmacologically-relevant concentrations in nonenhancing GBM tissue, and sensitizes brain tumor tissue to radiation ex vivo.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2022
Lead Product(s) : Pamiparib,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Ivy Brain Tumor Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pamiparib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Hutchmed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2022
Lead Product(s) : Pamiparib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Hutchmed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pamiparib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NMPA approval of pamiparib for patients with advanced ovarian, is based on clinical results from a pivotal Phase 2 portion of the Phase 1/2 trial. First PARP inhibitor approved in both platinum-sensitive and platinum-resistant relapsed ovarian cancer in ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2021
Lead Product(s) : Pamiparib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Pamiparib in Newly Diagnosed and rGBM
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 04, 2020
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2020
Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China
Details : The NDA of pamiparib as a potential treatment for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer was accepted in July 2020. It is supported by clinical results from the pivotal Phase 2 portion of the Phase 1/2 trial.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Pamiparib,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Clinical and nonclinical data on its anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in two mini oral presentations and five posters at the 2020 European Society for Medical Oncology (ESMO) Virtual Congr...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2020
Lead Product(s) : Pamiparib,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BeiGene downgrades late-stage study of PARP inhibitor in gastric cancer
Details : The global Phase 3, is designed to compare the efficacy and safety of pamiparib to placebo as maintenance therapy in approximately 540 patients with advanced gastric cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2020
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2019
Lead Product(s) : Pamiparib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2019
Lead Product(s) : Pamiparib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable